Skip to main content
Top
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide

Authors: Tao Yan, Kai Ove Skaftnesmo, Lina Leiss, Linda Sleire, Jian Wang, Xingang Li, Per Øyvind Enger

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Expression of neuronal elements has been identified in various glial tumors, and glioblastomas (GBMs) with neuronal differentiation patterns have reportedly been associated with longer survival. However, the neuronal class III β-tubulin has been linked to increasing malignancy in astrocytomas. Thus, the significance of neuronal markers in gliomas is not established.

Methods

The expressions of class III β-tubulin, neurofilament protein (NFP), microtubule-associated protein 2 (MAP2) and neuron-specific enolase (NSE) were investigated in five GBM cell lines and two GBM biopsies with immunocytochemistry and Western blot. Moreover, the expression levels were quantified by real-time qPCR under different culture conditions. Following NSE siRNA treatment we used Electric cell-substrate impedance sensing (ECIS) to monitor cell growth and migration and MTS assays to study viability after irradiation and temozolomide treatment. Finally, we quantitated NSE expression in a series of human glioma biopsies with immunohistochemistry using a morphometry software, and collected survival data for the corresponding patients. The biopsies were then grouped according to expression in two halves which were compared by survival analysis.

Results

Immunocytochemistry and Western blotting showed that all markers except NFP were expressed both in GBM cell lines and biopsies. Notably, qPCR demonstrated that NSE was upregulated in cellular stress conditions, such as serum-starvation and hypoxia, while we found no uniform pattern for the other markers. NSE knockdown reduced the migration of glioma cells, sensitized them to hypoxia, radio- and chemotherapy. Furthermore, we found that GBM patients in the group with the highest NSE expression lived significantly shorter than patients in the low-expression group.

Conclusions

Neuronal markers are aberrantly expressed in human GBMs, and NSE is consistently upregulated in different cellular stress conditions. Knockdown of NSE reduces the migration of GBM cells and sensitizes them to hypoxia, radiotherapy and chemotherapy. In addition, GBM patients with high NSE expression had significantly shorter survival than patients with low NSE expression. Collectively, these data suggest a role for NSE in the adaption to cellular stress, such as during treatment.
Appendix
Available only for authorised users
Literature
1.
go back to reference Eng LF: Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol. 1985, 8 (4-6): 203-214.CrossRefPubMed Eng LF: Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol. 1985, 8 (4-6): 203-214.CrossRefPubMed
2.
go back to reference Linskey ME, Gilbert MR: Glial differentiation: a review with implications for new directions in neuro-oncology. Neurosurgery. 1995, 36 (1): 1-21. 10.1227/00006123-199501000-00001. discussion 21-22CrossRefPubMed Linskey ME, Gilbert MR: Glial differentiation: a review with implications for new directions in neuro-oncology. Neurosurgery. 1995, 36 (1): 1-21. 10.1227/00006123-199501000-00001. discussion 21-22CrossRefPubMed
3.
go back to reference Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006, 9 (3): 157-173. 10.1016/j.ccr.2006.02.019.CrossRefPubMed Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al: Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006, 9 (3): 157-173. 10.1016/j.ccr.2006.02.019.CrossRefPubMed
4.
go back to reference Prestegarden L, Enger PO: Cancer stem cells in the central nervous system--a critical review. Cancer Res. 2010, 70 (21): 8255-8258. 10.1158/0008-5472.CAN-10-1592.CrossRefPubMed Prestegarden L, Enger PO: Cancer stem cells in the central nervous system--a critical review. Cancer Res. 2010, 70 (21): 8255-8258. 10.1158/0008-5472.CAN-10-1592.CrossRefPubMed
5.
go back to reference Donev K, Scheithauer BW, Rodriguez FJ, Jenkins S: Expression of diagnostic neuronal markers and outcome in glioblastoma. Neuropathol Appl Neurobiol. 2010, 36 (5): 411-421. 10.1111/j.1365-2990.2010.01078.x.CrossRefPubMed Donev K, Scheithauer BW, Rodriguez FJ, Jenkins S: Expression of diagnostic neuronal markers and outcome in glioblastoma. Neuropathol Appl Neurobiol. 2010, 36 (5): 411-421. 10.1111/j.1365-2990.2010.01078.x.CrossRefPubMed
6.
go back to reference Varlet P, Soni D, Miquel C, Roux FX, Meder JF, Chneiweiss H, Daumas-Duport C: New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases. Neurosurgery. 2004, 55 (6): 1377-1391. discussion 1391-1372CrossRefPubMed Varlet P, Soni D, Miquel C, Roux FX, Meder JF, Chneiweiss H, Daumas-Duport C: New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases. Neurosurgery. 2004, 55 (6): 1377-1391. discussion 1391-1372CrossRefPubMed
7.
go back to reference Prestegarden L, Svendsen A, Wang J, Sleire L, Skaftnesmo KO, Bjerkvig R, Yan T, Askland L, Persson A, Sakariassen P, et al: Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res. 2010, 70 (11): 4274-4279. 10.1158/0008-5472.CAN-09-3904.CrossRefPubMed Prestegarden L, Svendsen A, Wang J, Sleire L, Skaftnesmo KO, Bjerkvig R, Yan T, Askland L, Persson A, Sakariassen P, et al: Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res. 2010, 70 (11): 4274-4279. 10.1158/0008-5472.CAN-09-3904.CrossRefPubMed
8.
go back to reference Katsetos CD, Del Valle L, Geddes JF, Assimakopoulou M, Legido A, Boyd JC, Balin B, Parikh NA, Maraziotis T, de Chadarevian JP, et al: Aberrant localization of the neuronal class III beta-tubulin in astrocytomas. Arch Pathol Lab Med. 2001, 125 (5): 613-624.PubMed Katsetos CD, Del Valle L, Geddes JF, Assimakopoulou M, Legido A, Boyd JC, Balin B, Parikh NA, Maraziotis T, de Chadarevian JP, et al: Aberrant localization of the neuronal class III beta-tubulin in astrocytomas. Arch Pathol Lab Med. 2001, 125 (5): 613-624.PubMed
9.
go back to reference Wharton SB, Chan KK, Whittle IR: Microtubule-associated protein 2 (MAP-2) is expressed in low and high grade diffuse astrocytomas. J Clin Neurosci. 2002, 9 (2): 165-169. 10.1054/jocn.2001.1055.CrossRefPubMed Wharton SB, Chan KK, Whittle IR: Microtubule-associated protein 2 (MAP-2) is expressed in low and high grade diffuse astrocytomas. J Clin Neurosci. 2002, 9 (2): 165-169. 10.1054/jocn.2001.1055.CrossRefPubMed
10.
go back to reference Giannini C, Scheithauer BW, Lopes MB, Hirose T, Kros JM, VandenBerg SR: Immunophenotype of pleomorphic xanthoastrocytoma. Am J Surg Pathol. 2002, 26 (4): 479-485. 10.1097/00000478-200204000-00010.CrossRefPubMed Giannini C, Scheithauer BW, Lopes MB, Hirose T, Kros JM, VandenBerg SR: Immunophenotype of pleomorphic xanthoastrocytoma. Am J Surg Pathol. 2002, 26 (4): 479-485. 10.1097/00000478-200204000-00010.CrossRefPubMed
11.
go back to reference Perry A, Scheithauer BW, Macaulay RJ, Raffel C, Roth KA, Kros JM: Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications. J Neuropathol Exp Neurol. 2002, 61 (11): 947-955.CrossRefPubMed Perry A, Scheithauer BW, Macaulay RJ, Raffel C, Roth KA, Kros JM: Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications. J Neuropathol Exp Neurol. 2002, 61 (11): 947-955.CrossRefPubMed
12.
go back to reference Rodriguez FJ, Scheithauer BW, Robbins PD, Burger PC, Hessler RB, Perry A, Abell-Aleff PC, Mierau GW: Ependymomas with neuronal differentiation: a morphologic and immunohistochemical spectrum. Acta Neuropathol. 2007, 113 (3): 313-324. 10.1007/s00401-006-0153-x.CrossRefPubMed Rodriguez FJ, Scheithauer BW, Robbins PD, Burger PC, Hessler RB, Perry A, Abell-Aleff PC, Mierau GW: Ependymomas with neuronal differentiation: a morphologic and immunohistochemical spectrum. Acta Neuropathol. 2007, 113 (3): 313-324. 10.1007/s00401-006-0153-x.CrossRefPubMed
13.
go back to reference Tlhyama T, Lee VM, Trojanowski JQ: Co-expression of low molecular weight neurofilament protein and glial fibrillary acidic protein in established human glioma cell lines. Am J Pathol. 1993, 142 (3): 883-892.PubMedPubMedCentral Tlhyama T, Lee VM, Trojanowski JQ: Co-expression of low molecular weight neurofilament protein and glial fibrillary acidic protein in established human glioma cell lines. Am J Pathol. 1993, 142 (3): 883-892.PubMedPubMedCentral
14.
go back to reference Akslen LA, Andersen KJ, Bjerkvig R: Characteristics of human and rat glioma cells grown in a defined medium. Anticancer Res. 1988, 8 (4): 797-803.PubMed Akslen LA, Andersen KJ, Bjerkvig R: Characteristics of human and rat glioma cells grown in a defined medium. Anticancer Res. 1988, 8 (4): 797-803.PubMed
15.
go back to reference Bjerkvig R, Tonnesen A, Laerum OD, Backlund EO: Multicellular tumor spheroids from human gliomas maintained in organ culture. J Neurosurg. 1990, 72 (3): 463-475. 10.3171/jns.1990.72.3.0463.CrossRefPubMed Bjerkvig R, Tonnesen A, Laerum OD, Backlund EO: Multicellular tumor spheroids from human gliomas maintained in organ culture. J Neurosurg. 1990, 72 (3): 463-475. 10.3171/jns.1990.72.3.0463.CrossRefPubMed
16.
go back to reference Sakariassen PO, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R, Molthoff C, Sminia P, Sundlisaeter E, Misra A, Tysnes BB, et al: Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA. 2006, 103 (44): 16466-16471. 10.1073/pnas.0607668103.CrossRefPubMedPubMedCentral Sakariassen PO, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R, Molthoff C, Sminia P, Sundlisaeter E, Misra A, Tysnes BB, et al: Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA. 2006, 103 (44): 16466-16471. 10.1073/pnas.0607668103.CrossRefPubMedPubMedCentral
17.
go back to reference Malich G, Markovic B, Winder C: The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology. 1997, 124 (3): 179-192. 10.1016/S0300-483X(97)00151-0.CrossRefPubMed Malich G, Markovic B, Winder C: The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology. 1997, 124 (3): 179-192. 10.1016/S0300-483X(97)00151-0.CrossRefPubMed
18.
go back to reference Katsetos CD, Dráberová E, Legido A, Dumontet C, Dráber P: Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. J Cell Physiol. 2009, 221 (3): 505-513. 10.1002/jcp.21870.CrossRefPubMed Katsetos CD, Dráberová E, Legido A, Dumontet C, Dráber P: Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. J Cell Physiol. 2009, 221 (3): 505-513. 10.1002/jcp.21870.CrossRefPubMed
19.
go back to reference Marangos PJ, Schmechel DE, Parma AM, Goodwin FK: Developmental profile of neuron-specific (NSE) and non-neuronal (NNE) enolase. Brain Res. 1980, 190 (1): 185-193. 10.1016/0006-8993(80)91168-3.CrossRefPubMed Marangos PJ, Schmechel DE, Parma AM, Goodwin FK: Developmental profile of neuron-specific (NSE) and non-neuronal (NNE) enolase. Brain Res. 1980, 190 (1): 185-193. 10.1016/0006-8993(80)91168-3.CrossRefPubMed
20.
go back to reference Watanabe M, Nagamine T, Sakimura K, Takahashi Y, Kondo H: Developmental study of the gene expression for alpha and gamma subunits of enolase in the rat brain by in situ hybridization histochemistry. J Comp Neurol. 1993, 327 (3): 350-358. 10.1002/cne.903270304.CrossRefPubMed Watanabe M, Nagamine T, Sakimura K, Takahashi Y, Kondo H: Developmental study of the gene expression for alpha and gamma subunits of enolase in the rat brain by in situ hybridization histochemistry. J Comp Neurol. 1993, 327 (3): 350-358. 10.1002/cne.903270304.CrossRefPubMed
21.
go back to reference Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004, 4 (11): 891-899. 10.1038/nrc1478.CrossRefPubMed Gatenby RA, Gillies RJ: Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004, 4 (11): 891-899. 10.1038/nrc1478.CrossRefPubMed
22.
go back to reference Vinores SA, Bonnin JM, Rubinstein LJ, Marangos PJ: Immunohistochemical demonstration of neuron-specific enolase in neoplasms of the CNS and other tissues. Arch Pathol Lab Med. 1984, 108 (7): 536-540.PubMed Vinores SA, Bonnin JM, Rubinstein LJ, Marangos PJ: Immunohistochemical demonstration of neuron-specific enolase in neoplasms of the CNS and other tissues. Arch Pathol Lab Med. 1984, 108 (7): 536-540.PubMed
23.
go back to reference Vinores SA, Marangos PJ, Bonnin JM, Rubinstein LJ: Immunoradiometric and immunohistochemical demonstration of neuron-specific enolase in experimental rat gliomas. Cancer Res. 1984, 44 (6): 2595-2599.PubMed Vinores SA, Marangos PJ, Bonnin JM, Rubinstein LJ: Immunoradiometric and immunohistochemical demonstration of neuron-specific enolase in experimental rat gliomas. Cancer Res. 1984, 44 (6): 2595-2599.PubMed
24.
go back to reference Hattori T, Takei N, Mizuno Y, Kato K, Kohsaka S: Neurotrophic and neuroprotective effects of neuron-specific enolase on cultured neurons from embryonic rat brain. Neurosci Res. 1995, 21 (3): 191-198. 10.1016/0168-0102(94)00849-B.CrossRefPubMed Hattori T, Takei N, Mizuno Y, Kato K, Kohsaka S: Neurotrophic and neuroprotective effects of neuron-specific enolase on cultured neurons from embryonic rat brain. Neurosci Res. 1995, 21 (3): 191-198. 10.1016/0168-0102(94)00849-B.CrossRefPubMed
25.
go back to reference Kuramitsu M, Sawa H, Takeshita I, Iwaki T, Kato K: Neuron-specific gamma-enolase derived from human glioma. Neurochem Pathol. 1986, 4 (2): 89-105.PubMed Kuramitsu M, Sawa H, Takeshita I, Iwaki T, Kato K: Neuron-specific gamma-enolase derived from human glioma. Neurochem Pathol. 1986, 4 (2): 89-105.PubMed
26.
go back to reference Scatena R, Bottoni P, Pontoglio A, Mastrototaro L, Giardina B: Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs. 2008, 17 (10): 1533-1545. 10.1517/13543784.17.10.1533.CrossRefPubMed Scatena R, Bottoni P, Pontoglio A, Mastrototaro L, Giardina B: Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs. 2008, 17 (10): 1533-1545. 10.1517/13543784.17.10.1533.CrossRefPubMed
27.
go back to reference Amberger-Murphy V: Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets. 2009, 9 (3): 381-390. 10.2174/156800909788166637.CrossRefPubMed Amberger-Murphy V: Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets. 2009, 9 (3): 381-390. 10.2174/156800909788166637.CrossRefPubMed
28.
go back to reference Hamaguchi T, Iizuka N, Tsunedomi R, Hamamoto Y, Miyamoto T, Iida M, Tokuhisa Y, Sakamoto K, Takashima M, Tamesa T, et al: Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int J Oncol. 2008, 33 (4): 725-731.PubMed Hamaguchi T, Iizuka N, Tsunedomi R, Hamamoto Y, Miyamoto T, Iida M, Tokuhisa Y, Sakamoto K, Takashima M, Tamesa T, et al: Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int J Oncol. 2008, 33 (4): 725-731.PubMed
29.
go back to reference Tsai ST, Chien IH, Shen WH, Kuo YZ, Jin YT, Wong TY, Hsiao JR, Wang HP, Shih NY, Wu LW: ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer. 2010, 46 (9): 1712-1723. 10.1016/j.ejca.2010.03.018.CrossRefPubMed Tsai ST, Chien IH, Shen WH, Kuo YZ, Jin YT, Wong TY, Hsiao JR, Wang HP, Shih NY, Wu LW: ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer. 2010, 46 (9): 1712-1723. 10.1016/j.ejca.2010.03.018.CrossRefPubMed
30.
go back to reference Petrovic M, Tomic I, Plavec G, Ilic S, Ilic N, Baskic D: Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer. J BUON. 2008, 13 (1): 93-96.PubMed Petrovic M, Tomic I, Plavec G, Ilic S, Ilic N, Baskic D: Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer. J BUON. 2008, 13 (1): 93-96.PubMed
31.
go back to reference Makretsov N, Gilks CB, Coldman AJ, Hayes M, Huntsman D: Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol. 2003, 34 (10): 1001-1008. 10.1053/S0046-8177(03)00411-8.CrossRefPubMed Makretsov N, Gilks CB, Coldman AJ, Hayes M, Huntsman D: Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol. 2003, 34 (10): 1001-1008. 10.1053/S0046-8177(03)00411-8.CrossRefPubMed
32.
go back to reference Berner A, Harvei S, Tretli S, Fossa SD, Nesland JM: Prostatic carcinoma: a multivariate analysis of prognostic factors. Br J Cancer. 1994, 69 (5): 924-930. 10.1038/bjc.1994.179.CrossRefPubMedPubMedCentral Berner A, Harvei S, Tretli S, Fossa SD, Nesland JM: Prostatic carcinoma: a multivariate analysis of prognostic factors. Br J Cancer. 1994, 69 (5): 924-930. 10.1038/bjc.1994.179.CrossRefPubMedPubMedCentral
33.
go back to reference Allen FJ, Van Velden DJ, Heyns CF: Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer?. Br J Urol. 1995, 75 (6): 751-754. 10.1111/j.1464-410X.1995.tb07385.x.CrossRefPubMed Allen FJ, Van Velden DJ, Heyns CF: Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer?. Br J Urol. 1995, 75 (6): 751-754. 10.1111/j.1464-410X.1995.tb07385.x.CrossRefPubMed
34.
go back to reference Vos MJ, Postma TJ, Martens F, Uitdehaag BM, Blankenstein MA, Vandertop WP, Slotman BJ, Heimans JJ: Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study. Anticancer Res. 2004, 24 (4): 2511-2514.PubMed Vos MJ, Postma TJ, Martens F, Uitdehaag BM, Blankenstein MA, Vandertop WP, Slotman BJ, Heimans JJ: Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study. Anticancer Res. 2004, 24 (4): 2511-2514.PubMed
35.
go back to reference Ayoub MS, Baghdadi HM, El-Kholy M: Immunohistochemical detection of laminin-1 and Ki-67 in radicular cysts and keratocystic odontogenic tumors. BMC Clin Pathol. 2011, 11: 4-10.1186/1472-6890-11-4.CrossRefPubMedPubMedCentral Ayoub MS, Baghdadi HM, El-Kholy M: Immunohistochemical detection of laminin-1 and Ki-67 in radicular cysts and keratocystic odontogenic tumors. BMC Clin Pathol. 2011, 11: 4-10.1186/1472-6890-11-4.CrossRefPubMedPubMedCentral
36.
go back to reference Katsetos CD, Draberova E, Legido A, Dumontet C, Draber P: Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. J Cell Physiol. 2009, 221 (3): 505-513. 10.1002/jcp.21870.CrossRefPubMed Katsetos CD, Draberova E, Legido A, Dumontet C, Draber P: Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. J Cell Physiol. 2009, 221 (3): 505-513. 10.1002/jcp.21870.CrossRefPubMed
Metadata
Title
Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide
Authors
Tao Yan
Kai Ove Skaftnesmo
Lina Leiss
Linda Sleire
Jian Wang
Xingang Li
Per Øyvind Enger
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-524

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine